A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

This study is looking for adults aged 18 and over who have been recently diagnosed with multiple myeloma. A key requirement is that you are not suitable for a stem cell transplant, either because of your age (usually 65 or older) or other health problems that make a transplant too risky. You would also need to have clear signs of multiple myeloma that can be measured by your doctor.

There are certain reasons why you might not be able to join. For example, if you have other types of blood conditions like smoldering multiple myeloma or Waldenström's Macroglobulinemia. Additionally, if you have an active, uncontrolled infection (like a serious bacterial, fungal, or viral infection, including HIV or serious COVID-19), or another active cancer that isn't completely cured, you wouldn't be able to participate. If you've previously had a specific type of treatment that targets BCMA this might also stop you from joining.

If you join this study, the doctors will first make sure the new drug combination is safe. Then, you will be given either the new combination treatment or the standard treatment. Both treatments involve taking several different medications, some of which may be given as injections or infusions, and others as tablets. You would have regular appointments at the hospital for check-ups, blood tests, and to receive your medication. The doctors will closely monitor how you're responding to the treatment and for any side effects. The exact number of visits and the total length of time you'd be involved can vary, but studies like this usually involve follow-up for several years to track your long-term health and the cancer's progress.